TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18360659
Drug: Periodontal initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Periodontal initial therapy
Study: 16737046
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with high CD4 count (group 1A)
Study: 16737046
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with low CD4 count (group 1B)
Study: 16737046
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine (20 micrograms per dose) in normal healthy controls (group II)
Study: 16737046
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine in all groups (HIV-positive and controls)
Study: 16737046
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine in patients with high CD4 count
Study: 16737046
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine in patients with low CD4 count
Study: 16737046
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine in patients with CD4 count < 50
Study: 1881582
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody OKT3
Study: 6348424
Drug: 2 day
Normalized name: Sterapred 12 DAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin)
Study: 6348424
Drug: 5 day
Normalized name: Fresh 5 Day Deodorant Pads
DrugBank: Aluminum chlorohydrate (DB11573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin followed by 3 days of oral cephalexin)
Study: 26977602
Drug: Solution-focused CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused CBT (SFT)
Study: 26977602
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PML and SFT)
Study: 21917299
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (quinapril, losartan, amlodipine, hydrochlorothiazide, or bisoprolol) for 6 months
Study: 12471004
Drug: Granisetron 20
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 20 micro g/kg
Study: 12471004
Drug: Ramosetron 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 4 micro g/kg
Study: 9796881
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (single dose)
Study: 9796881
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg (once daily for 10 days)
Study: 9796881
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (once daily for 10 days)
Study: 9796881
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 10 days)
Study: 7549418
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Vasoactive Intestinal Polypeptide (VIP)
Study: 7549418
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Substance P (SP)
Study: 2229528
Drug: Terbinafine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (125 mg taken twice daily)
Study: 31344386
Drug: Topical coal
Normalized name: coal tar Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical coal tar treatment
Study: 30251749
Drug: Ultrasound-guided interfascial
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided interfascial injection (US-IFI)
Study: 27150460
Drug: Lactoferrin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin and lactoperoxidase-containing tablets
Study: 26187496
Drug: Lamotrigine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (up to 200mg per day, up to 400mg if taking combined oral contraceptives)
Study: 19702677
Drug: UFH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH plus GP IIb/IIIa inhibitor
Study: 17365760
Drug: Gabapentin 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,800 mg/day for 8 weeks
Study: 15231010
Drug: Oral intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intermittent ibandronate (20 mg every other day for 12 doses every 3 months)
Study: 15231010
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate (daily and intermittent)
Study: 11234783
Drug: Patient-delivered partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-delivered partner medication (PDPM) for women
Study: 11234783
Drug: Patient-delivered partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-delivered partner medication (PDPM) for casual partners
Study: 9678620
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day for 5 years) in adjuvant studies
Study: 9678620
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day for 5 years) in chemoprevention study
Study: 8053589
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rocuronium and mivacurium (1 ED50 rocuronium + 1 ED50 mivacurium, etc.)
Study: 8053589
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rocuronium 150 micrograms.kg-1 + Mivacurium 37.5 micrograms.kg-1 (Group 3)
Study: 2903169
Drug: Idazoxan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (40 mg, orally)
Study: 2903169
Drug: Idazoxan (iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (iv administration 20 min before GIT)
Study: 29490632
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICPIs)
Study: 29440887
Drug: Arformoterol 15
Normalized name: arformoterol 15 mcg/2 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arformoterol 15 µg, twice daily
Study: 23502689
Drug: Online self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-help cognitive behavioral therapy (CBT) package (Overcoming Bulimia Online)
Study: 19069453
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) with aspirin (125 mg thrice daily)
Study: 19069453
Drug: Chronotherapy (ChN)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapy (ChN) with aspirin taken once daily at 22.00
Study: 16809906
Drug: PSE/DAG (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSE/DAG (1.2 g PSE/30 g DAG for 2 weeks)
Study: 14719295
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment in the treatment group
Study: 14719295
Drug: Drugs in
Normalized name: Other antiobesity drugs in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs in the control group
Study: 9208339
Drug: Incadronate (0.025-1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incadronate (0.025-1.6 mg) in healthy volunteers
Study: 9208339
Drug: Incadronate (2.5-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incadronate (2.5-10.0 mg) in patients with malignancy-associated hypercalcemia
Study: 7956408
Drug: Simple saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple saline solution nasal irrigation
Study: 18294083
Drug: extended-release mixed
Normalized name: Amphetamine Mixed Salts Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: extended-release mixed amphetamine salts (se-AMPH ER, 30 mg)
Study: 10602721
Drug: Oral cefaclor
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefaclor
Study: 31852538
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (Arm 3)
Study: 27936169
Drug: Synbiotic (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic (1.5 × 10^10 CFU Ecologic® 825 + 10 g fructo‐oligosaccharides (FOS P6) per day)
Study: 19225400
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) once daily
Study: 19225400
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) twice daily
Study: 19225400
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) once daily and twice daily
Study: 15562775
Drug: estradiol velerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estradiol velerate (E2V) 1.0 mg/d and medroxyprogestetone acetate (MPA) 2 mg/d
Study: 8989263
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at a mean dose of 0.128 +/- 0.003 IU/kg.week for the first month, then 0.23 +/- 0.01 IU/kg.week, divided into daily doses (0.7-4.3 IU/day)
Study: 7684225
Drug: Iloprost applied
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost applied as an aqueous solution, hydrogels, and fatty ointment at dose levels of at least 50/25 ng/cm2 (intact/stripped skin)
Study: 7684225
Drug: Iloprost applied
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost applied at high doses (400/150 ng/cm2)
Study: 7684225
Drug: Iloprost applied
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost applied at a dose of 25 micrograms/100 cm2 once daily for 60 days
Study: 20497745
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) alone for 6 days
Study: 20497745
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) co-administered with linagliptin (10 mg/day) for 6 days
Study: 19096711
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation (Triomune)
Study: 12628519
Drug: Chlorophyllin (CHL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorophyllin (CHL), administered three times a day
Study: 8256356
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine treatment
Study: 3512670
Drug: Chlorthalidone 25.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25.0 mg
Study: 3512670
Drug: Chlorthalidone 50.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50.0 mg
Study: 29788364
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 injection plus monthly 50,000 IU maintenance therapy
Study: 26176640
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to send biological data to doctors
Study: 23790699
Drug: Dutch 10-session
Normalized name: ditch stonecroft extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutch 10-session community occupational therapy programme
Study: 18079998
Drug: alpha-Lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-Lipoic acid (LA) supplementation with hyperbaric oxygen therapy (HBO)
Study: 18079998
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with hyperbaric oxygen therapy (HBO)
Study: 16583576
Drug: Savlon douching
Normalized name: Savlon Dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savlon douching (1:1000 solution)
Study: 16583576
Drug: Povidone-iodine painting
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine painting (1% solution)
Study: 11204664
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery infusion alternating with systemic therapy (oxaliplatin and fluorouracil (5-FU) with leucovorin)
Study: 11204664
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxaliplatin and fluorouracil (5-FU)
Study: 9309270
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Study: 9309270
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Study: 9309270
Drug: Effervescent calcium
Normalized name: Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin)
Study: 3736281
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg Ro 17-1812
Study: 3736281
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg Ro 17-1812
Study: 3736281
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg Ro 17-1812
Study: 28231946
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg b.i.d.
Study: 28231946
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg b.i.d.
Study: 28231946
Drug: Benznidazole 200
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 200 mg + Posaconazole 400 mg b.i.d.
Study: 28231946
Drug: Benznidazole 200
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 200 mg b.i.d.
Study: 28231946
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg b.i.d. (30 days)
Study: 28231946
Drug: Benznidazole 200
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 200 mg b.i.d. (30 days)
Study: 28231946
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg b.i.d. (60 days)
Study: 28231946
Drug: Benznidazole 200
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 200 mg b.i.d. (60 days)
Study: 28231946
Drug: Benznidazole monotherapy
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole monotherapy (360 days)
Study: 24088749
Drug: sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin + metformin
Study: 19624691
Drug: Acute metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute metabolic acidosis induced by administration of ammonium chloride (NH4Cl)
Study: 19624691
Drug: Acute metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute metabolic acidosis induced by administration of ammonium chloride (NH4Cl) in COPD patients
Study: 15266766
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose Femarelle (644 mg/day)
Study: 15266766
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Femarelle (344 mg/day)
Study: 11497198
Drug: Perindopril (P)
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril (P) therapy
Study: 11497198
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (UC)
Study: 3067951
Drug: Human Actrapid
Normalized name: Human Actrapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Actrapid (three times daily pre-prandial doses using a NovoPen) plus Human Ultratard (n = 19)
Study: 3067951
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin (n = 18)
Study: 27543905
Drug: Topical tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tocopherol acetate
Study: 25534576
Drug: Temozolomide 150
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150 mg/m² days 1-7 and 15-21, every 28 days for 8 cycles
Study: 21546875
Drug: Bethanechol chloride
Normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bethanechol chloride (Ucholine 20 mg 3 times a day on the third to seventh postoperative day)
Study: 16434866
Drug: Levofloxacin-azithromycin combined
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-azithromycin combined triple therapy (omeprazole 20 mg bid, levofloxacin 500 mg od, azithromycin 500 mg od) for 7 days
Study: 16434866
Drug: Levofloxacin-azithromycin combined
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-azithromycin combined triple therapy for second-line eradication
Study: 16434866
Drug: Standard PPI-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PPI-based triple therapy (omeprazole 20 mg bid, amoxicillin 1.0 g bid, clarithromycin 500 mg bid) for 7 days
Study: 16434866
Drug: Bismuth-based quadruple
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based quadruple therapy (omeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, tetracycline 500 mg qid) for second-line eradication
Study: 12606508
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 mg/day, n = 4)
Study: 12606508
Drug: Metformin (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (approximately 2,000 mg/day, n = 8)
Study: 16245220
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 IU/day) plus Vitamin C (500 mg/day)
Study: 9588606
Drug: Protonics device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protonics device during activities of daily living (ADL)
Study: 7518020
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (2 cycles of cis-platinum 100 mg/m2, bleomycin 10 mg/m2 loading dose, followed by 10 mg/m2/day continuous infusion, and vinblastine 3 mg/m2)
Study: 7518020
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy group
Study: 2609062
Drug: 50% DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% DMSO gel
Study: 9295
Drug: Salbutamol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (4 mg 3 times a day)
Study: 30646129
Drug: Primaquine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine treatment (high-dose)
Study: 30646129
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no primaquine treatment)
Study: 10372711
Drug: L‐T4 substitutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 substitutive therapy (mean dose, 68 microg daily)
Study: 10372711
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with subclinical hypothyroidism (before treatment)
Study: 26963483
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAAs) 6 g consumed 10 min before exercise and exercise therapy (twice weekly for 3 months)
Study: 26963483
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maltodextrin 6 g consumed 10 min before exercise and exercise therapy)
Study: 26963483
Drug: BCAAs administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCAAs administration
Study: 26963483
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BCAA intake and exercise therapy
Study: 18060212
Drug: Paracetamol 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1500 mg/day
Study: 16264047
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment including bosentan, sildenafil, and inhaled iloprost
Study: 7783014
Drug: Implant overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant overdentures with O-ring attachments
Study: 7783014
Drug: Implant overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant overdentures with magnet attachments
Study: 2191111
Drug: Systemic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic metronidazole (three 400 mg tablets daily for 1 week)
Study: 31422216
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) of single-agent chemotherapy (methotrexate, docetaxel, or cetuximab)
Study: 21917518
Drug: Anthracycline-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based treatment
Study: 15496698
Drug: Corticosteroids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids treatment in head injury (intervention group where consent was waived)
Study: 15496698
Drug: Corticosteroids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids treatment in head injury (control group where consent was required)